Novo Nordisk A/S

• The GLP-1 agonists market is projected to experience substantial growth by 2034, driven by increased awareness and efficacy in managing diabetes and obesity. • Key players like Novo Nordisk, AstraZeneca, and Viking Therapeutics are developing innovative GLP-1 agonists, including oral formulations, to enhance patient adherence. • Emerging therapies such as VK2735, TERN-601, and ECC5004 are poised to transform the market with improved efficacy and novel mechanisms of action. • GLP-1 agonists are gaining traction beyond diabetes, showing promise in treating obesity and non-alcoholic fatty liver disease (NAFLD), expanding their therapeutic potential.

• The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. • This growth is fueled by the introduction of novel therapies targeting NASH, with several drugs in Phase II and Phase III clinical trials showing promise for improving treatment outcomes. • Key players such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Novo Nordisk are actively developing innovative treatments, contributing to a dynamic and competitive market landscape. • The increasing prevalence of NASH and the growing understanding of its pathophysiology are driving the demand for effective therapies, creating opportunities for pharmaceutical companies.

• The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine. • Phase III trials currently dominate the market due to their large participant numbers and high costs, while Phase I trials are expected to grow fastest. • Oncology leads the market by indication, fueled by the rising prevalence of cancer and the need for more effective treatment strategies. • North America currently holds the largest market share, supported by favorable regulatory frameworks and a growing emphasis on personalized medicine.

• The omics-based clinical trials market is projected to reach USD 70.92 billion by 2034, driven by the increasing adoption of personalized medicine. • Phase III trials currently dominate the market due to their large participant numbers and high costs, while Phase I trials are expected to grow fastest. • Oncology leads the market by indication, fueled by the rising prevalence of cancer and the need for more effective treatment strategies. • North America currently holds the largest market share, supported by favorable regulatory frameworks and a growing emphasis on personalized medicine.

• Viking Therapeutics' obesity pill demonstrated an average of 6.8% body weight loss over 28 days in early-stage trials, showing promising potential in weight management. • AstraZeneca's weight-loss pill showed a 5.8% weight reduction in diabetic patients, indicating efficacy in a specific population with differential outcomes. • The obesity drug market is projected to reach $130 billion by the end of the decade, intensifying competition among pharmaceutical giants like Eli Lilly and Novo Nordisk. • Pharmaceutical companies are focusing on developing convenient oral medications with minimal side effects to capture a significant share of the expanding obesity treatment market.

• Roche remains confident in its obesity drug candidates despite initial concerns over side effects observed in a small study of CT-388, a weight-loss shot. • The company emphasizes that no patients discontinued treatment due to side effects, which included nausea, vomiting, and diarrhea. • Roche is optimistic about CT-966, an oral weight-loss drug, suggesting it has the potential to be a 'best-in-class' treatment option. • The pharmaceutical giant is actively seeking partnerships in antibody-drug conjugates to diversify its oncology portfolio.